Singapore markets open in 8 hours 55 minutes
Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,156.78 +28.99 (+0.57%) Dow
38,722.96 +47.28 (+0.12%) Nasdaq
16,267.86 +111.54 (+0.69%) Bitcoin USD
63,654.73 -758.30 (-1.18%) CMC Crypto 200
1,368.80 +56.18 (+4.28%)
SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:03PM EDT. Market open.
| Previous close | 45.11 |
| Open | 45.81 |
| Bid | 45.22 x 200 |
| Ask | 45.52 x 100 |
| Day's range | 44.61 - 45.81 |
| 52-week range | 18.00 - 53.92 |
| Volume | |
| Avg. volume | 1,169,915 |
| Market cap | 3.355B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
R&D Expenses: R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. Net Loss: Net loss widened to $325.1 million in 2023, with a loss per share of $5.15.
© 2024 Yahoo. All rights reserved.